Medicus Pharma signs Pfizer co‑development deal for CD228V and announces $135 M SPAC proposal for SkinJect
Medicus Pharma Ltd. entered a co‑development and worldwide license agreement with Pfizer Inc. for the melanoma‑targeted ADC CD228V, under which Pfizer provided $2 million in development funding. The company also disclosed a non‑binding letter of intent with an undisclosed special purpose acquisition company to combine with its SkinJect subsidiary at an approximate $135 million pre‑money valuation. The partnership and proposed transaction are intended to fund ongoing clinical programs and support a potential NDA filing for SkinJect in Gorlin syndrome.
Why it matters
The $2 million Pfizer funding reduces Medicus’s near‑term cash burn for CD228V development, while the SPAC deal could bring equity financing of up to $135 million to advance SkinJect’s registrational study, potentially diluting existing shareholders if completed. The company expects to continue advancing both programs regardless of the SPAC closing.
Key facts
- 1Medicus entered a co‑development and license agreement with Pfizer for CD228V on September 2 2026, granting an exclusive worldwide license to develop, manufacture and commercialize the program. stocktitan.net
- 2Pfizer provided $2.0 million in development funding under the agreement and retains the right, without obligation, to fund later stages. stocktitan.net
- 3Medicus announced on November 4 2026 a non‑binding LOI with an undisclosed SPAC for a proposed business combination involving its SkinJect subsidiary. stocktitan.net
- 4The LOI contemplates an approximate $135 million pre‑money enterprise valuation for SkinJect and concurrent equity financing at closing to support the SkinJect 005 study and a potential NDA. finanznachrichten.de
- 5Medicus reported cash, cash equivalents and restricted cash of $13.1 million as of September 30 2026. finanznachrichten.de
- 6Net loss for Q3 2026 was $15.2 million, with a net loss per share of $11.64 after a 50‑to‑1 share consolidation effective October 12 2026. finanznachrichten.de
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.